Table 2.
Clinical and pathological data according to the evolution of kidney disease
| Clinical and pathological data | Progressive kidney disease (n = 20) | Non-progressive kidney disease (n = 54) | P-value |
|---|---|---|---|
| Age | 45 ± 16 | 37 ± 13 | 0·053 |
| Female | 5 (25) | 19 (35·2) | 0·23 |
| Hypertensive | 18 (90) | 26 (49·1) | 0·001 |
| Previous macroscopic haematuria | 6 (33·3) | 21 (40·4) | 0·6 |
| eGFR (ml/min per 1·73 m2) | 31 ± 22 | 81 ± 31 | <0·005 |
| Proteinuria (g/day) | 3·907 ± 2·155 | 1·835 ± 1·372 | <0·005 |
| Immunosuppressive therapy | 5 (26·3) | 11 (23·4) | ≅1 |
| IgM positivity | 10 (50) | 18 (34) | 0·21 |
| IgG positivity | 5 (26·3) | 14 (26·9) | 0·96 |
| C1q positivity | 2 (10·5) | 8 (16) | 0·715 |
| S1 score | 8 (40) | 29 (53·7) | 0·295 |
| E1 score | 3 (15·0) | 5 (9·3) | 0·674 |
| T1–2 score | 17 (85) | 8 (15·4) | <0·005 |
| C4d positivity | 11 (55) | 14 (27·5) | 0·029 |
| TGase-2 G score | 1·35 ± 0·26 | 1·26 ± 0·29 | 0·19 |
| High TGase-2 T score | 16 (84·2) | 15 (33·3) | <0·005 |
| p-ERK1/2 score | 1·33 ± 0·68 | 1·32 ± 0·54 | 0·9 |
| CD3 score | 66 273 ± 39 311 | 19 322 ± 20 632 | <0·005 |
For quantitative variables, values are expressed as the mean ± standard deviation. For qualitative variables, values are expressed as n (%). Progressive kidney disease, defined as a decline of at least 50% in the glomerular filtration rate (GFR) or progression to end-stage renal disease (ESRD) during the follow-up period. Immunoglobulin (Ig)M, IgG and C1q refer to the results of routine immunofluorescence data. S1, E1 and T1–2 according to the Oxford classification reanalysis of the biopsies. High TGase-2 T score (>25% staining). eGFR = estimated glomerular filtration rate.